This document lists 12 APIs and provides information on their pharmaceutical use, trade names, and regulatory status. Several APIs like mefenamic acid, talniflumate, and tolfenamic acid are non-steroidal anti-inflammatory drugs with commercial production for non-regulatory markets and some with US DMF or SFDA filings planned or in progress. Calcium-based combination amino acids for renal insufficiency are in the product license approval process with the SFDA. Fexofenadine, venlafaxine, edaravone and doxapram have various regulatory filings planned within the next year.
Untuk menjamin aksesibilitas, ketersediaan dan keterjangkauan obat, serta penggunaan obat secara rasional dalam pelaksanaan Jaminan Kesehatan Nasional, Menteri Kesehatan telah menetapkan Formularium Nasional (ForNas), sebagai acuan dalam penyediaan dan penggunaan obat dalam JKN. Harga obat yang tercantum dalam ForNas akan dicantumkan dalam e-catalog obat dari LKPP.
Untuk menjamin aksesibilitas, ketersediaan dan keterjangkauan obat, serta penggunaan obat secara rasional dalam pelaksanaan Jaminan Kesehatan Nasional, Menteri Kesehatan telah menetapkan Formularium Nasional (ForNas), sebagai acuan dalam penyediaan dan penggunaan obat dalam JKN. Harga obat yang tercantum dalam ForNas akan dicantumkan dalam e-catalog obat dari LKPP.
Presentation on data integrity in Pharmaceutical IndustrySathish Vemula
Presentation on data integrity in Pharmaceutical Industry
Contents:
- Definition & Basics
- Criteria for integrity of laboratory data
- Regulatory Requirements
- Barriers to Complete Data
- Possible data integrity problems
- Previous observations
- FDA Warning Letters – 2013
- FDA Warning Letters – 2014
- FDA 483’s related to data integrity
- EU – Non compliance Reports
- WHO - Notice of Concern
- Summary of Data Integrity issues
- Consequences- Rebuilding Trust
- Conclusion
Presentation on data integrity in Pharmaceutical IndustrySathish Vemula
Presentation on data integrity in Pharmaceutical Industry
Contents:
- Definition & Basics
- Criteria for integrity of laboratory data
- Regulatory Requirements
- Barriers to Complete Data
- Possible data integrity problems
- Previous observations
- FDA Warning Letters – 2013
- FDA Warning Letters – 2014
- FDA 483’s related to data integrity
- EU – Non compliance Reports
- WHO - Notice of Concern
- Summary of Data Integrity issues
- Consequences- Rebuilding Trust
- Conclusion
1. APIs List
APIs List
No. API CAS # Pharmaceutical Status
non‐steroidal anti‐inflammatory US DMF filed. Inspected by US FDA for prior approval of API
1 Mefenamic acid 61‐68‐7
61 68 7 drug (NSAID).
drug (NSAID) with no 483. ANDA approval is expected end of 2012.
with no 483 ANDA approval is expected end of 2012
Tradename: PONSTEL Commercial production presently for non‐regulatory market
Anitinflammatory,
mucoregulator. No SFDA file, but in commercial production for non‐
2 Talniflumate 66898‐62‐2
Tradename TALMAIN (Korea), regulatory market
LOMUCIN
non‐steroidal anti‐inflammatory
drug (NSAID). Tradename: No SFDA file, but in commercial production for non‐
3 Tolfenamic acid 13710‐19‐5
CLOTAM regulatory market
Calcium
4 51828 93 4
51828‐93‐4
Phenylpyruvate
5 α‐Ketovaline Calcium 51828‐94‐5 Combination of amino acids for
6 α‐Ketoleucine Calcium 51828‐95‐6 use in managing protein Product licenses approved by SFDA. Final documentation
D,L‐α‐Ketoisoleucine metabolism during renal underway. SFDA inspection expected in 2Q 2013 with
7 66872‐75‐1
Calcium insufficiency. Tradename: approval thereafter.
y y
2‐Hydroxy‐4‐ Ketosteril
8 (methylthio)butyric 4857‐44‐7
acid calcium salt
Antihistamine, In commercial production for non‐regulatory market.
9 Fexofenadine HCl 15439‐40‐8
Tradename: Allegra US DMF in preparation will be filed in Q4, 2012
Antidepressant
10 Venlafaxine 93413‐69‐5 In commercial production for non‐regulatory market.
Tradename: Effexor
Tradename: Effexor
Stroke recovery Process development completed, documents will be filed
11 Edaravone 89‐25‐8
Traded by Mitsubishi with SFDA in Q2 2013
Respiratory stimulant. Process development completed and US DMF will be filed
12 Doxapram 7081‐53‐0
Tradename: Dopram with FDA in Q3 2013